# OnCo record isb-2001 (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/isb-2001/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "isb-2001" ;
  schema:name "ISB 2001"@en ;
  schema:description "An Indian-discovered antibody that grips two targets on myeloma cells at once while pulling in T cells to kill them, licensed to AbbVie in 2025 in the biggest deal yet for an Indian cancer drug."@en ;
  schema:url <https://onco.cc/drugs/isb-2001/> ;
  schema:dateModified "2026-09-10"^^xsd:date ;
  schema:citation <https://www.glenmarkpharma.com> ;
  onco:status "phase-1" ;
  onco:modality "Trispecific T-cell engager (BCMA x CD38 x CD3)" ;
  onco:related <https://onco.cc/drugs/teclistamab/>, <https://onco.cc/drugs/talquetamab/> ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/t-cell-engager/>, <https://onco.cc/technologies/bispecific-antibody/> ;
  onco:targets <https://onco.cc/targets/bcma/>, <https://onco.cc/targets/cd38/> ;
  onco:companies <https://onco.cc/companies/glenmark/>, <https://onco.cc/companies/abbvie/> ;
  onco:trials <https://onco.cc/trials/nct05862012/> ;
  onco:bottlenecks <https://onco.cc/bottlenecks/b-translational-valley/> .